

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



# 石四藥集團有限公司 SSY Group Limited

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 2005)**

## **VOLUNTARY ANNOUNCEMENT UPDATE ON PRODUCT DEVELOPMENT**

The board of directors (the “Board”) of SSY Group Limited (the “Company”, together with its subsidiaries, the “Group”) is pleased to announce that the Group has obtained the approval for drug production and registration for Levofloxacin Eye Drops (0.488% (5ml : 24.4mg)) from National Medical Products Administration of China (the “NMPA”), being under type 4 chemical drug and regarded as passing the consistency evaluation. Levofloxacin Eye Drops are mainly used in treatment of blepharitis, meibomianitis, dacryocystitis, conjunctivitis, meibomian gland dysfunction, keratitis, and aseptic chemotherapy for the perioperative period of ophthalmology. This approval further enriches the Group’s portfolio of different types of ophthalmic preparations.

The Board is also pleased to announce that the Group has obtained the approval for drug production and registration for Compound Sodium Picosulfate Granules (10mg of Sodium Picosulfate per bag) from the NMPA, being under type 3 and regarded as passing the consistency evaluation. Compound Sodium Picosulfate Granules are mainly used in bowel cleansing preparation before colonoscopy and X-ray examinations, and can also be used in bowel cleansing before surgical procedures. As stated in the Company’s announcement dated 4 December 2025, the Group’s Sodium Picosulfate bulk drug has obtained the approval for registration from the NMPA to become a bulk drug for the preparations on the market.

This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group.

By order of the Board  
**Chow Hing Yeung**  
*Executive Director and Company Secretary*

Hong Kong, 9 December 2025

*As at the date of this announcement, the Board comprises Mr. Qu Jiguang, Mr. Su Xuejun, Mr. Meng Guo, Mr. Chow Hing Yeung and Ms. Qu Wanrong as executive Directors, Mr. Liu Wenjun as non-executive Director, and Mr. Wang Yibing, Mr. Chow Kwok Wai and Mr. Jiang Guangce as independent non-executive Directors.*